Skip to main content
. 2015 Mar 20;42(8):1304–1314. doi: 10.1007/s00259-015-3025-6

Fig. 9.

Fig. 9

18F-FDG PET/CT and 89Zr-rituximab immuno-PET/CT images in patient 2 obtained 6 days after injection with and without a preload of unlabelled rituximab show lower tracer uptake in involved lymph nodes with the preload (white arrows), but higher uptake in less accessible visceral lesions (oesophagus and stomach; blue arrows) resulting in better tumour targeting